TVTX Q3 2025 Earnings — Travere Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TVTXTravere Therapeutics, Inc.

$3B

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$165M+162.1% YoY

Gross Profit

$163M99.0% margin

Operating Income

$25M15.1% margin

Net Income

$26M15.6% margin

EPS (Diluted)

$0.25

QoQ Revenue Growth

+44.0%

Cash Flow

Operating Cash Flow

$14M

Free Cash Flow

$14M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$539M

Total Liabilities

$465M

Stockholders' Equity

$74M

Cash & Equivalents

$111M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$165M	$63M	+162.1%
Gross Profit	$163M	$61M	+166.5%
Operating Income	$25M	-$56M	+144.4%
Net Income	$26M	-$55M	+146.9%

Revenue Segments

Product

$113M69%

License

$52M31%

Geographic Segments

Non-US

$42M100%